Form 4: Altimmune Director Vipin Garg's RSU Vesting & Tax Sale

Altimmune Director Vipin Garg reported the vesting of 41,200 Restricted Stock Units and the subsequent sale of 17,898 shares to cover tax obligations.

Summary

• Vipin K. Garg, a Director at Altimmune, Inc., reported transactions related to his beneficial ownership.
• On January 27, 2026, 41,200 Restricted Stock Units (RSUs) vested, converting into an equal number of common shares.
• Concurrently, 17,898 shares of common stock were disposed of at a price of $6.18 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Garg directly beneficially owns 402,450 shares of common stock and 123,600 unvested Restricted Stock Units.
• The RSUs vest in substantially equal annual installments over four years starting January 27, 2025, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for insider compensation disclosures. It reflects the routine vesting of equity awards and a tax-related sale, not a discretionary market action.

Positives

• The vesting of RSUs indicates continued compensation and alignment of director interests with shareholder value.

Negatives

• The sale of shares, while for tax purposes, represents a reduction in direct beneficial ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the remaining Restricted Stock Units.

Industry Context

StockSavvy.ai notes that insider transaction filings like Form 4 are routine disclosures for public company directors and officers. The vesting of Restricted Stock Units and subsequent sale for tax purposes is a common practice in executive compensation, reflecting the realization of equity awards rather than a discretionary market sale.

Comparison to Industry Standards

• The structure of equity compensation through Restricted Stock Units with a multi-year vesting schedule is a standard practice across various industries, including biotechnology, aligning executive incentives with long-term company performance.
• The disposition of shares solely to cover tax obligations upon vesting is a common and expected event, often facilitated by a Rule 10b5-1 plan, and is not typically indicative of a change in management's outlook on the company's prospects.

Related Party Transactions

• The vesting of Restricted Stock Units and the subsequent tax-related share disposition are transactions between a director and the issuer, which are considered related-party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect the planned compensation of a director. The sale of shares for tax purposes is not a discretionary sale and is unlikely to signal a change in confidence.
• Employees: No direct impact on employees is indicated.

Next Steps

• Future annual installments of the remaining 123,600 Restricted Stock Units will vest, subject to Vipin K. Garg's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent tax-related sale. Such events are pre-scheduled and are not typically indicative of a change in the company's fundamental outlook or a discretionary investment decision by the insider. Therefore, it provides no new information that would warrant a change in an investor's current position, maintaining a 'hold' recommendation based solely on this filing.

Keywords

Altimmune, ALT, Vipin Garg, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Compensation, Equity Compensation, Tax Withholding